SCHEMBL1507066

SCHEMBL1507066

COc1cncc(Cl)c1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15664805 0.85
SCHEMBL744752 0.82 CYP1A1 (0.61)
SCHEMBL6833539 0.77 APP (0.50)
SCHEMBL5550636 0.77 CHRNB2 (0.57)
SCHEMBL7054960 0.76
SCHEMBL12282882 0.76 CHRNB2 (0.47)
SCHEMBL30310124 0.76 CHRNB2 (0.61)
SCHEMBL2614843 0.76 CHRNB2 (0.61)
SCHEMBL6764164 0.76 CHRNB2 (0.47)
SCHEMBL14154914 0.76 MAP4K4 (0.55)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1304325-A1 5-(M-CYANOBENZYLAMINO)PYRAZOLE DERIVATIVES Sankyo Company, Limited (JP) 2003-04-23 EP claimed
US-12606541-B2 PPARg modulators and methods of use EISAI R&D MANAGEMENT CO., LTD. (JP) 2026-04-21 US disclosed
CN-119569648-A Novel energetic compound and preparation method thereof 信阳师范学院 2025-03-07 CN disclosed
US-20230062861-A1 PPARg MODULATORS AND METHODS OF USE EISAI R&D MANAGEMENT CO., LTD. (JP) 2023-03-02 US disclosed
EP-3442955-B1 SELECTIVE D3 DOPAMINE RECEPTOR AGONISTS AND METHODS OF THEIR USE US HEALTH (US) 2021-09-29 EP disclosed
US-10618926-B2 Process for making phosphoramidate protected nucleoside compounds MERCK SHARP & DOHME (US) 2020-04-14 US disclosed
US-10000507-B2 Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors INCYTE CORPORATION (US) 2018-06-19 US disclosed
US-20180111954-A1 PROCESS FOR MAKING PHOSPHORAMIDATE PROTECTED NUCLEOSIDE COMPOUNDS MERCK SHARP & DOHME CORP. (US) 2018-04-26 US disclosed
WO-2017181004-A1 SELECTIVE D3 DOPAMINE RECEPTOR AGONISTS AND METHODS OF THEIR USE THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2017-10-19 WO disclosed
US-20170275327-A1 SUBSTITUTED PHOSPHORAMIDATE COMPOUNDS AND USES THEREOF MERCK SHARP & DOHME LLC 2017-09-28 US disclosed
CN-1907969-A Benzoylpyridine derivative or its salt, disinfectant containing the same as active ingredient method for producing the same and intermediate for producing the same ISHIHARA SANGYO KAISHA (JP) 2007-02-07 CN disclosed
CN-1635877-A Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance NEUROSEARCH AS (DK) 2005-07-06 CN disclosed
WO-2004069256-A1 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF NOVARTIS AG (CH) 2004-08-19 WO disclosed
US-20040092508-A1 Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance ANIONA APS (DK) 2004-05-13 US disclosed
EP-1358177-A2 TREATMENT OF AFFECTIVE DISORDERS BY THE COMBINED ACTION OF A NICOTINIC RECEPTOR AGONIST AND A MONOAMINERGIC SUBSTANCE NeuroSearch A/S (DK) 2003-11-05 EP disclosed
CN-1440389-A Benzoylpyridine derivative or its salt, fungicide containing it as active ingredient, its production method and intermediate for producing it ISHIHARA SANGYO KAISHA (JP) 2003-09-03 CN disclosed
EP-1304325-A1 5-(M-CYANOBENZYLAMINO)PYRAZOLE DERIVATIVES Sankyo Company, Limited (JP) 2003-04-23 EP disclosed
WO-2003020721-A1 PYRROLO PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CYSTEIN PROTEASES NOVARTIS AG (CH) 2003-03-13 WO disclosed
WO-2002030405-A2 TREATMENT OF AFFECTIVE DISORDERS BY THE COMBINED ACTION OF A NICOTINIC RECEPTOR AGONIST AND A MONOAMINERGIC SUBSTANCE NEUROSEARCH A/S (DK) 2002-04-18 WO disclosed
US-4713080-A OXIDATIVE COLORING WELLA AKTIENGESELLSCHAFT (DE) 1987-12-15 US disclosed